Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.07.2022 | Case report

Fulvestrant/palbociclib

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Matiz GA, et al. CO107 Progression-Free Survival in Patients with Advanced or Metastatic, Hormone Receptor Positive, HER2-Negative Breast Cancer Treated with Palbociclib in Combination with Fulvestrant: A Real-World Study. Value in Health 25 (Spec. issue 7): S324, Jul 2022. Available from: URL: http://doi.org/10.1016/j.jval.2022.04.203 [abstract] Matiz GA, et al. CO107 Progression-Free Survival in Patients with Advanced or Metastatic, Hormone Receptor Positive, HER2-Negative Breast Cancer Treated with Palbociclib in Combination with Fulvestrant: A Real-World Study. Value in Health 25 (Spec. issue 7): S324, Jul 2022. Available from: URL: http://​doi.​org/​10.​1016/​j.​jval.​2022.​04.​203 [abstract]
Metadaten
Titel
Fulvestrant/palbociclib
Lack of efficacy: case report
Publikationsdatum
01.07.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-20153-2

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Olanzapine

Case report

Multiple drugs

Case report

Antineoplastics

Case report

Nivolumab